Latest posts
-
Oncocyte Reports Third Quarter 2023 Financial Results
-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, CA, November 09, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights Josh Riggs, CEO
-
Oncocyte to Announce Third Quarter 2023 Financial Results
Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, November 3, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m.
-
Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
[et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”] Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data
-
Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA, September 6, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel. Josh